×
S&P 500   3,895.35 (+1.31%)
DOW   31,341.12 (+0.98%)
QQQ   293.85 (+1.75%)
AAPL   145.83 (+2.04%)
MSFT   267.80 (+0.60%)
META   171.41 (+0.97%)
GOOGL   2,345.08 (+2.34%)
AMZN   116.04 (+1.50%)
TSLA   726.80 (+4.55%)
NVDA   157.93 (+4.38%)
NIO   22.35 (+7.30%)
BABA   123.78 (+3.91%)
AMD   79.27 (+5.20%)
MU   58.52 (+2.00%)
CGC   2.67 (+0.75%)
T   21.17 (+0.38%)
GE   62.35 (+1.27%)
F   11.58 (+4.70%)
DIS   97.04 (+1.00%)
AMC   13.94 (+10.90%)
PFE   53.10 (+0.66%)
PYPL   74.67 (+1.95%)
NFLX   189.10 (+2.74%)
S&P 500   3,895.35 (+1.31%)
DOW   31,341.12 (+0.98%)
QQQ   293.85 (+1.75%)
AAPL   145.83 (+2.04%)
MSFT   267.80 (+0.60%)
META   171.41 (+0.97%)
GOOGL   2,345.08 (+2.34%)
AMZN   116.04 (+1.50%)
TSLA   726.80 (+4.55%)
NVDA   157.93 (+4.38%)
NIO   22.35 (+7.30%)
BABA   123.78 (+3.91%)
AMD   79.27 (+5.20%)
MU   58.52 (+2.00%)
CGC   2.67 (+0.75%)
T   21.17 (+0.38%)
GE   62.35 (+1.27%)
F   11.58 (+4.70%)
DIS   97.04 (+1.00%)
AMC   13.94 (+10.90%)
PFE   53.10 (+0.66%)
PYPL   74.67 (+1.95%)
NFLX   189.10 (+2.74%)
S&P 500   3,895.35 (+1.31%)
DOW   31,341.12 (+0.98%)
QQQ   293.85 (+1.75%)
AAPL   145.83 (+2.04%)
MSFT   267.80 (+0.60%)
META   171.41 (+0.97%)
GOOGL   2,345.08 (+2.34%)
AMZN   116.04 (+1.50%)
TSLA   726.80 (+4.55%)
NVDA   157.93 (+4.38%)
NIO   22.35 (+7.30%)
BABA   123.78 (+3.91%)
AMD   79.27 (+5.20%)
MU   58.52 (+2.00%)
CGC   2.67 (+0.75%)
T   21.17 (+0.38%)
GE   62.35 (+1.27%)
F   11.58 (+4.70%)
DIS   97.04 (+1.00%)
AMC   13.94 (+10.90%)
PFE   53.10 (+0.66%)
PYPL   74.67 (+1.95%)
NFLX   189.10 (+2.74%)
S&P 500   3,895.35 (+1.31%)
DOW   31,341.12 (+0.98%)
QQQ   293.85 (+1.75%)
AAPL   145.83 (+2.04%)
MSFT   267.80 (+0.60%)
META   171.41 (+0.97%)
GOOGL   2,345.08 (+2.34%)
AMZN   116.04 (+1.50%)
TSLA   726.80 (+4.55%)
NVDA   157.93 (+4.38%)
NIO   22.35 (+7.30%)
BABA   123.78 (+3.91%)
AMD   79.27 (+5.20%)
MU   58.52 (+2.00%)
CGC   2.67 (+0.75%)
T   21.17 (+0.38%)
GE   62.35 (+1.27%)
F   11.58 (+4.70%)
DIS   97.04 (+1.00%)
AMC   13.94 (+10.90%)
PFE   53.10 (+0.66%)
PYPL   74.67 (+1.95%)
NFLX   189.10 (+2.74%)
NASDAQ:ONTX

Onconova Therapeutics Stock Forecast, Price & News

$1.37
+0.06 (+4.58%)
(As of 07/7/2022 12:22 PM ET)
Add
Compare
Today's Range
$1.32
$1.37
50-Day Range
$1.04
$1.44
52-Week Range
$1.00
$6.77
Volume
590 shs
Average Volume
74,674 shs
Market Capitalization
$28.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Onconova Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
657.6% Upside
$10.00 Price Target
Short Interest
Healthy
0.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of Onconova Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.79) to ($0.74) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.67 out of 5 stars

Medical Sector

789th out of 1,433 stocks

Pharmaceutical Preparations Industry

402nd out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ONTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Onconova Therapeutics logo

About Onconova Therapeutics (NASDAQ:ONTX) Stock

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

ONTX Stock News Headlines

Recap: Onconova Therapeutics Q4 Earnings
Onconova Therapeutics FY Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONTX
Employees
14
Year Founded
N/A

Company Calendar

Last Earnings
5/11/2022
Today
7/07/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+629.9%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
3 Analysts

Profitability

Net Income
$-16,160,000.00
Net Margins
-6,889.38%
Pretax Margin
-6,889.38%

Debt

Sales & Book Value

Annual Sales
$230,000.00
Book Value
$2.22 per share

Miscellaneous

Free Float
20,645,000
Market Cap
$28.63 million
Optionable
Not Optionable
Beta
1.61














Onconova Therapeutics Frequently Asked Questions

Should I buy or sell Onconova Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Onconova Therapeutics stock.
View analyst ratings for Onconova Therapeutics
or view top-rated stocks.

What is Onconova Therapeutics' stock price forecast for 2022?

3 Wall Street analysts have issued 1-year price objectives for Onconova Therapeutics' stock. Their ONTX stock forecasts range from $7.00 to $12.00. On average, they predict Onconova Therapeutics' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 629.9% from the stock's current price.
View analysts' price targets for Onconova Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Onconova Therapeutics' stock performed in 2022?

Onconova Therapeutics' stock was trading at $2.55 on January 1st, 2022. Since then, ONTX shares have decreased by 46.3% and is now trading at $1.37.
View the best growth stocks for 2022 here
.

When is Onconova Therapeutics' next earnings date?

Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Onconova Therapeutics
.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) released its quarterly earnings data on Wednesday, May, 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.02. The biopharmaceutical company earned $0.06 million during the quarter, compared to analysts' expectations of $0.06 million. Onconova Therapeutics had a negative trailing twelve-month return on equity of 36.41% and a negative net margin of 6,889.38%. During the same quarter last year, the firm earned ($0.30) earnings per share.
View Onconova Therapeutics' earnings history
.

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Onconova Therapeutics shares reverse split on the morning of Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 20th 2021. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the following people:
  • Dr. Steven M. Fruchtman M.D., CEO, Pres & Director (Age 71, Pay $903.45k) (LinkedIn Profile)
  • Mr. Mark Patrick Guerin CPA, CFO & COO (Age 53, Pay $578.4k)
  • Dr. Adar Makovski Silverstein Ph.D., Sr. Director & Head of Corp. Devel.
  • Dr. Mark Stephen Gelder M.D., Chief Medical Officer (Age 65)

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

How do I buy shares of Onconova Therapeutics?

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $1.37.

How much money does Onconova Therapeutics make?

Onconova Therapeutics (NASDAQ:ONTX) has a market capitalization of $28.63 million and generates $230,000.00 in revenue each year. The biopharmaceutical company earns $-16,160,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis.

How many employees does Onconova Therapeutics have?

Onconova Therapeutics employs 14 workers across the globe.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The official website for Onconova Therapeutics is www.onconova.com. The biopharmaceutical company can be reached via phone at (267) 759-3680, via email at ir@onconova.us, or via fax at 267-759-3681.

This page (NASDAQ:ONTX) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.